projects the broader obesity drug market could approach $200 billion by 2030 as adoption expands globally and indications broaden beyond diabetes and weight management
Antonie Van Leeuwenhoek 99 (4), 761771
Many patients report NSVs ("non-scale victories") such as increased energy, better sleep, reduced joint pain, and improved confidence as they shed weight
If you are not losing weight on tirzepatide at your current dose, discuss options with your provider rather than self-adjusting
Reviewed against primary medical, regulatory, and trial sources for accuracy, sourcing, and patient-safety framing
FurinDB: a database of 20-residue furin cleavage site motifs, substrates and their associated drugs